April 28, 2022
- A Translational Lens on Synergistic Cancer Therapy: Insights from Our Recent Case Study
- Redesigning Preclinical Oncology: A Framework for Improving Clinical Translatability with AI, RECIST-Inspired Metrics, and Systems-Level Thinking
- Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know
- Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus
- The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know
A Translational Lens on Synergistic Cancer Therapy: Insights from Our Recent Case Study
In cancer drug development, monotherapies often lose ground when tumors adapt. This is especially true for KRASmutant non–small cell lung cancers ...
Redesigning Preclinical Oncology: A Framework for Improving Clinical Translatability with AI, RECIST-Inspired Metrics, and Systems-Level Thinking
Despite decades of investment in oncology drug development, the translational pipeline from preclinical models to clinical success remains ...
Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know
The FDA has issued a new draft guidance titled “Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development.” This ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
